Diamond Scientific Co. v. Ambico, Inc.

666 F. Supp. 163, 4 U.S.P.Q. 2d (BNA) 1327, 1987 U.S. Dist. LEXIS 7276
CourtDistrict Court, S.D. Iowa
DecidedAugust 12, 1987
DocketCiv. No. 86-796-A
StatusPublished
Cited by3 cases

This text of 666 F. Supp. 163 (Diamond Scientific Co. v. Ambico, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. Iowa primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Diamond Scientific Co. v. Ambico, Inc., 666 F. Supp. 163, 4 U.S.P.Q. 2d (BNA) 1327, 1987 U.S. Dist. LEXIS 7276 (S.D. Iowa 1987).

Opinion

RULING AND ORDER

STUART, District Judge.

This is an action for patent infringement brought by the assignee of the patents against the inventor-assignor and the company of which he is founder, majority stockholder and president. As affirmative defenses to that action, defendants allege: (1) in the second affirmative defense that the patents are void and invalid under 35 U.S.C. § 112 relating to the specification requirements; (2) in the third affirmative defense, that the patents are void and invalid because they lack the novelty required by 35 U.S.C. § 102; in the sixth affirmative defense, that the patents are void and invalid under 35 U.S.C. § 103 because of prior art and obviousness.

Plaintiff has moved to strike these affirmative defenses on the ground that an assignor is estopped from urging the invalidity of the patents that he has assigned to another. Defendants claim that the doctrine of assignor estoppel is no longer a viable doctrine. That is the prime issue before the court.

In 1959 Clarence J. Welter was employed by Diamond Laboratories, Inc., plaintiffs predecessor. While so employed, he invented “Transmissible Gastroenteritis Vaccines and Methods of Producing the Same.” On September 18, 1964, while he was making application for Letters Patent, he assigned all his right in any patents obtained to Diamond Laboratories, Inc. Based upon Welter’s application the following patents were granted to plaintiff’s predecessor.

Patent No. 3,479,430 November 18, 1969

Patent No. 3,585,108 June 15, 1971

Patent No. 3,704,203 November 28, 1972

In connection with his patent applications Welter signed an “Oath, Power of Attorney and Petition” containing, in part, the following language:

I have read the foregoing specification and claims and I verily believe I am the original, first and sole inventor of the invention in [TGE vaccines] described and claimed therein; that I do not know and do not believe that this invention was ever known or used before my invention thereof, or patented or described in any printed publication in any country, before my invention thereof; or more than one year prior to this application, or in public use or sale in the United States for more than one year prior to this application. ...

In 1974 Welter left plaintiff’s employment and formed Ambico, Inc., the defendant corporation, and serves as its president. Since its formation, Ambico Inc. has made and sold Transmissible Gastroenteritis (TGE) vaccine.

Plaintiff filed this action October 31, 1986 alleging that the defendants are infringing upon these patents by making, using, and/or selling of modified live virus [TGE] vaccine, and instructing others to use vaccine made and supplied by defendants in an infringing manner.

[165]*165DISCUSSION

In Westinghouse Co. v. Formica, 266 U.S. 342, 349, 45 S.Ct. 117, 119-20, 69 L.Ed. 316 (1924) the United States Supreme Court approved of the following rule:

[A]n assignor of a patent right is estopped to attack the utility, novelty or validity of a patented invention which he has assigned or granted as against any one claiming the right under his assignment or grant. As to the rest of the world, the patent may have no efficacy and create no right of monopoly; but the assignor can not be heard to question the right of his assignee to exclude him from its use.

This rule is directly on point and if this is still the law, plaintiffs’ motion to strike the affirmative defenses must be granted. However, defendants argue that the Supreme Court decision in Lear, Inc. v. Adkins, 395 U.S. 653, 89 S.Ct. 1902, 23 L.Ed.2d 610 (1969) made the assignor es-toppel rule defunct and cite recent authorities so holding.

Lear, Inc. dealt with the obligation of a licensee to pay royalties while challenging the validity of the patent on which the royalties were to be paid. The California Court, relying upon Automatic Radio Manufacturing Co. v. Hazeltine Research, Inc., 339 U.S. 827, 836, 70 S.Ct. 894, 899, 94 L.Ed. 1312 (1950) held that a licensee operating under a license agreement is es-topped to deny the validity of his licensor’s patent in a suit by the licensor for royalties under the agreement. The Supreme Court in Lear granted certiorari “to reconsider the validity of the Hazeltine rule in the light of our recent decisions emphasizing the strong federal policy favoring free competition in ideas which do not merit patent protection.” 395 U.S. at 656, 89 S.Ct. at 1904. The Supreme Court held that Hazel-tine “should no longer be regarded as sound law with respect to its ‘estoppel’ holding and that holding is now overruled.” 395 U.S. at 671, 89 S.Ct. at 1911.

Justice Harlan thoroughly reviewed the pertinent authorities and concluded that:

The uncertain status of licensee estop-pel in the case law is a product of judicial efforts to accomodate the competing demands of the common law of contracts and the federal law of patents. On the one hand, the law of contracts forbids a purchaser to repudiate his promises simply because he becomes dissatisfied with the bargain he has made. On the other hand, federal law requires that all ideas in general circulation be dedicated to the common good unless they are protected by a valid patent.

395 U.S. at 668, 89 S.Ct. at 1910.

Justice Harlan pointed out that the equities of the licensor who seeks to recover royalties despite his licensee’s attempts to show that the patent is invalid “are far from compelling” and they “do not weigh very heavily when they are balanced against the important public interest in permitting full and free competition in the use of ideas which are in reality a part of the public domain.” 395 U.S. at 670, 89 S.Ct. at 1911.

The cases appear to accept the proposition that there are competing demands between contract law and patent law. These demands must be balanced under the particular facts and in doing so the equities, principles of fair dealing, and interests of the public and the parties are considered. Completely different considerations are involved in licensee estoppel and assignor estoppel. When a patentee licensor is attempting to collect royalties on a patent of questionable validity from the licensee, he is seeking continued payments for a patent that may be worthless. The licensee would be required to charge the public more for the product to recover back the royalties paid. The public would “continually be required to pay tribute to would-be monopolists without need or justification.” 395 U.S. at 670, 89 S.Ct. at 1911. A licensor should not receive consideration for a worthless invention. It is proper for the contract doctrine to give way to the demands of the public interest in that situation.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
666 F. Supp. 163, 4 U.S.P.Q. 2d (BNA) 1327, 1987 U.S. Dist. LEXIS 7276, Counsel Stack Legal Research, https://law.counselstack.com/opinion/diamond-scientific-co-v-ambico-inc-iasd-1987.